Whitehawk Therapeutics, Inc.
WHWKNasdaq
$3.89
0.0%Jul 17 close · end-of-day
Price
1Y↑ +99.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$269.3M
Enterprise Value
$146.3M
P/E
—
P/S
—
P/B
2.3
EV/EBITDA
—
PEG
—
FCF Yield
-40.0%
Dividend Yield
—
Revenue (TTM)
$0.00
Net Income (TTM)
-$115.8M
Free Cash Flow (TTM)
-$107.8M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-99.7%
ROIC
—
Debt / Equity
—
Net Cash
$123.0M
Return 1Y
+110.3%
Company profile
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
- CEO
- David J. Lennon
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 21
- Headquarters
- New Jersey
- Website
- ir.whitehawktx.com
Earnings
WHWK Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00↓ -100.0%
Diluted EPS-$0.32↓ -117.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $14.0M | $14.0M | $15.2M | $24.4M | $26.0M | $7.1M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$2.5M | -$111.2M | -$62.7M | -$71.9M | -$67.5M | -$114.4M |
| Net income | -$3.5M | -$110.1M | -$60.5M | -$65.8M | -$63.7M | -$20.6M |
| Diluted EPS | — | -$12.41 | -$2.69 | -$2.44 | -$2.36 | -$0.33 |
| Operating cash flow | -$12.7M | -$22.4M | -$49.6M | -$59.7M | -$59.5M | -$97.4M |
| Free cash flow | -$12.7M | -$22.5M | -$50.1M | -$63.6M | -$61.2M | -$98.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -18.2% | -794.4% | -411.9% | -295.4% | -259.6% | -1601.1% |
| Net margin | -24.8% | -786.4% | -397.7% | -270.0% | -245.1% | -288.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.2M | $7.2M | $7.2M | $7.1M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$15.6M | -$13.4M | -$18.9M | -$15.2M | -$54.7M | -$19.5M | -$24.9M | -$23.5M |
| Net income | -$14.6M | -$12.5M | -$18.3M | $73.0M | -$52.6M | -$17.7M | -$23.3M | -$22.2M |
| Diluted EPS | -$0.54 | -$0.46 | -$0.68 | $1.83 | -$0.76 | -$0.26 | -$1.14 | -$0.32 |
| Operating cash flow | -$9.2M | -$15.7M | -$15.1M | -$11.9M | -$53.0M | -$15.4M | -$17.2M | -$22.2M |
| Free cash flow | -$9.7M | -$15.9M | -$15.2M | -$12.4M | -$53.0M | -$15.4M | -$17.2M | -$22.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -252.2% | -186.0% | -261.8% | -213.0% | — | — | — | — |
| Net margin | -236.0% | -174.0% | -252.4% | 1021.9% | — | — | — | — |
Company news
Jun 10, 2026
May 28, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.